arabinofuranosyluracil has been researched along with Lymphoma, Non-Hodgkin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Braess, J; Hiddemann, W; Kaufmann, C; Ramsauer, B; Schleyer, E; Schüssler, M; Unterhalt, M; Wilde, S | 1 |
| Büchner, T; Hiddemann, W; Kewer, U; Reuter, C; Rolf, C; Schleyer, E; Uhrmeister, C; Unterhalt, M; Wörmann, B; Zühlsdorf, M | 1 |
1 trial(s) available for arabinofuranosyluracil and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Pharmacokinetics of Ara-CMP-Stearate (YNK01): phase I study of the oral Ara-C derivative.
Topics: Administration, Oral; Antineoplastic Agents; Arabinofuranosyluracil; Arabinonucleotides; Cytarabine; Cytidine Monophosphate; Dose-Response Relationship, Drug; Half-Life; Humans; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Statistics, Nonparametric | 1995 |
1 other study(ies) available for arabinofuranosyluracil and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Differences in the intracellular pharmacokinetics of cytosine arabinoside (AraC) between circulating leukemic blasts and normal mononuclear blood cells.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Arabinofuranosyluracil; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Leukemia, Myeloid; Leukocytes, Mononuclear; Lymphoma, Non-Hodgkin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Thioguanine | 1992 |